ETFs & Funds
This user currently has no profile.
Stocks - long, Stocks - short, Tech stocks
Currently, there is no company profile for johnny881.
Currently, there are no blog details for johnny881.
Currently, there are no book details for johnny881.
Taking a long time to reach end point of 360 deaths in phase 3 clinical trial for colon cancer. Perifosine must be working amazingly well !
Mar 22, 2012
PATH on nasdaq is a future ...
Anacor Pharmaceuticals (ANAC +1%) files a mixed...
Put your profit into PATH (...
Research In Motion Is Up Over 100%: Time To Sell?
PATH on Nasdaq has blockbus...
Songa Offshore: A Fallen Angel With The Potenti...
PATH on nasdaq has PDUFA da...
Sarepta Therapeutics: No Problem With Cash
Yes ARNA could be a blockbu...
Assessing Arena's Belviq As A Diabesity Drug